ConductScience.org, home

Paper32255488

SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial.

McGovern BH and 20 others. Clin Infect Dis, 2021. Cited by 135 papers, by iCite.

Cite this record

ConductScience Library. SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Papers, record 32255488. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32255488

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial.
PubMed
Journal
Clin Infect Dis
PubMed
Year
2021
PubMed
Publication types
Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
135
iCite
Relative citation ratio, by iCite
8.29
iCite
Revised in PubMed
2024-04-02
PubMed

Authors21

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1McGovern BHBarbara Hhttps://orcid.org/0000-0003-4451-2393
2Ford CBChristopher B
3Henn MRMatthew R
4Pardi DSDarrell S
5Khanna SSahil
6Hohmann ELElizabeth L
7O'Brien EJEdward J
8Desjardins CAChristopher A
9Bernardo PPatricia
10Wortman JRJennifer R
11Lombardo MJMary-Jane
12Litcofsky KDKevin D
13Winkler JAJonathan A
14McChalicher CWJChristopher W J
15Li SSSunny S
16Tomlinson ADAmelia D
17Nandakumar MMadhumitha
18Cook DNDavid N
19Pomerantz RJRoger J
20Auninš JGJohn G

Source PubMed

See all 21 authorsDownload CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Clostridioides difficileMajor topic
Clostridium InfectionsMajor topic
MicrobiotaMajor topic
Aged
Clostridioides
Drugs, Investigational
Female
Humans
Male
Recurrence

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT02437487SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)Derived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in32330238Unexpected Results From a Phase 2 Trial of a Microbiome Therapeutic for Clostridioides difficile Infection: Lessons for the Future.https://conductscience.org/library/papers/32330238

Source PubMed

Download CSV of comments and corrections

References37

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
113655060Statistical aspects of the analysis of data from retrospective studies of disease.J Natl Cancer Inst1959https://conductscience.org/library/papers/13655060PubMed
232004427First Case of 2019 Novel Coronavirus in the United States.N Engl J Med2020https://conductscience.org/library/papers/32004427PubMed
331201853The perils of PCR-based diagnosis of Clostridioides difficile infections: Painful lessons from clinical trials.Anaerobe2019https://conductscience.org/library/papers/31201853PubMed
420089970Treatment with monoclonal antibodies against Clostridium difficile toxins.N Engl J Med2010https://conductscience.org/library/papers/20089970PubMed
524523597The epidemiology of irritable bowel syndrome.Clin Epidemiol2014https://conductscience.org/library/papers/24523597PubMed
632053787Regulatory Considerations for Fecal Microbiota Transplantation Products.Cell Host Microbe2020https://conductscience.org/library/papers/32053787PubMed
731665575Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant.N Engl J Med2019https://conductscience.org/library/papers/31665575PubMed
818199029Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea.J Infect Dis2008https://conductscience.org/library/papers/18199029PubMed
928220514
Randomised clinical trial: faecal microbiota transplantation for recurrent Clostridum difficile infection - fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy.
Aliment Pharmacol Ther2017https://conductscience.org/library/papers/28220514PubMed
1028531908Methods and Reporting Studies Assessing Fecal Microbiota Transplantation: A Systematic Review.Ann Intern Med2017https://conductscience.org/library/papers/28531908PubMed
1122688413Metagenomic microbial community profiling using unique clade-specific marker genes.Nat Methods2012https://conductscience.org/library/papers/22688413PubMed
1224098459Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole.PLoS One2013https://conductscience.org/library/papers/24098459PubMed
1326789728Changes in Colonic Bile Acid Composition following Fecal Microbiota Transplantation Are Sufficient to Control Clostridium difficile Germination and Growth.PLoS One2016https://conductscience.org/library/papers/26789728PubMed
1426169276Fecal Microbiota Transplantation Eliminates Clostridium difficile in a Murine Model of Relapsing Disease.Infect Immun2015https://conductscience.org/library/papers/26169276PubMed
1527444134High risk of post-infectious irritable bowel syndrome in patients with Clostridium difficile infection.Aliment Pharmacol Ther2016https://conductscience.org/library/papers/27444134PubMed
1629617739Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660-A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection.Clin Infect Dis2018https://conductscience.org/library/papers/29617739PubMed
1730957161Low Cure Rates in Controlled Trials of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis.Clin Infect Dis2019https://conductscience.org/library/papers/30957161PubMed
1819060152Chenodeoxycholate is an inhibitor of Clostridium difficile spore germination.J Bacteriol2009https://conductscience.org/library/papers/19060152PubMed
1926348734Overdiagnosis of Clostridium difficile Infection in the Molecular Test Era.JAMA Intern Med2015https://conductscience.org/library/papers/26348734PubMed
2027548329Are Microbial Politics Local?Ann Intern Med2016https://conductscience.org/library/papers/27548329PubMed

See all 37 referencesDownload CSV of references

Cited by95

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 135 citations.

PMIDTitleJournalYearIn PapersSource
42657533Microbiome-based therapeutics for Clostridioides difficile infection: additive, subtractive, and modulatory strategies in modern clinical practice.Gut Microbes2026https://conductscience.org/library/papers/42657533PubMed
42419269Ecological and dietary strategies to constrain Clostridioides difficile.Cell Host Microbe2026https://conductscience.org/library/papers/42419269PubMed
42379287The impact of fecal microbiota transplantation on host immunity and epithelial restoration following Clostridioides difficile infection.Anaerobe2026https://conductscience.org/library/papers/42379287PubMed
42288685Transplantation of encapsulated fecal microbiota: research progress and future trends.World J Pediatr2026https://conductscience.org/library/papers/42288685PubMed
41853554Live biotherapeutic products: a capstone for prevention of recurrent Clostridiodes difficile infection.Front Microbiomes2024https://conductscience.org/library/papers/41853554PubMed
41787017The gut as a central hub for multi-organ crosstalk in aging.Cell Mol Life Sci2026https://conductscience.org/library/papers/41787017PubMed
41698062Attenuated Bacteria-Based Tumor Therapy: Clinical Application Risks, Marketing Approval Restrictions, and Coping Strategies.Adv Sci (Weinh)2026https://conductscience.org/library/papers/41698062PubMed
41684675Targeting vaginal dysbiosis: prospects for the application of live biotherapeutics products.Front Microbiol2026https://conductscience.org/library/papers/41684675PubMed
41585029Long-Term Follow-Up After Fecal Microbiota Transplantation via Freeze-Dried Capsules for Recurrent Clostridioides difficile Infection.Pathog Immun2026https://conductscience.org/library/papers/41585029PubMed
41491103The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome.Nat Med2026https://conductscience.org/library/papers/41491103PubMed
41239968Design and application of synthetic human gut microbial communities.Gut Microbes2025https://conductscience.org/library/papers/41239968PubMed
41239747Development of Peptide Glucosyltransferase Inhibitors With Comprehensive Coverage Across Clostridioides difficile Toxin B Sub-Types.Biotechnol Bioeng2026https://conductscience.org/library/papers/41239747PubMed
41158525Mechanisms of Clostridioides difficile glucosyltransferase toxins and their roles in pathology: insights and emerging therapeutic strategies.Front Cell Infect Microbiol2025https://conductscience.org/library/papers/41158525PubMed
41126356Improving fecal transplantation precision for enhanced maturation of intestinal function in germ-free mice through microencapsulation and probiotic intervention.Microbiome2025https://conductscience.org/library/papers/41126356PubMed
41039491Gut bacteria: protective mediators, pathogenic contributors and novel therapeutic targets in Candida albicans infections.Gut Pathog2025https://conductscience.org/library/papers/41039491PubMed
40861872What's New and What's Next in Fecal Microbiota Transplantation?Biologics2025https://conductscience.org/library/papers/40861872PubMed
40751372Comparability of Gastrointestinal Microbiome and Bile Acid Profiles in Patients With First or Multiply Recurrent Clostridioides difficile Infection.J Infect Dis2025https://conductscience.org/library/papers/40751372PubMed
40705333Microbiota Transplantation Among Patients Receiving Long-Term Care: The Sentinel REACT Nonrandomized Clinical Trial.JAMA Netw Open2025https://conductscience.org/library/papers/40705333PubMed
40689613Differential modulation of post-antibiotic colonization resistance to Clostridioides difficile by two probiotic Lactobacillus strains.mBio2025https://conductscience.org/library/papers/40689613PubMed
40643244Straining to define a healthy microbiome.mSphere2025https://conductscience.org/library/papers/40643244PubMed

See all 95 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32255488

GET https://conductscience.org/api/papers/v1/32255488/authors?page=2